Tumor-infiltrating immune cell types predicting recurrence-free survival in melanoma patients receiving adjuvant PD-1 inhibitor therapy
BackgroundAdjuvant treatment of melanoma patients with PD-1-based immunotherapy has improved recurrence rate, and became a standard treatment. However, a considerable proportion of patients recur within 1–2 years, necessitating the identification of pr…